echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Hebo Pharmaceutical's new-generation anti-CTLA-4 antibody phase I clinical trial in China completed the first patient administration

    Hebo Pharmaceutical's new-generation anti-CTLA-4 antibody phase I clinical trial in China completed the first patient administration

    • Last Update: 2021-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Hebo Pharma announced that its anti-CTLA-4 antibody (HBM4003) has completed its first patient medication in an open phase I study (study number 4003.
    2) for patients with advanced melanoma and other solid tumors in China

    .
    In this study, HBM4003 was used in combination with teriprizumab (PD-1 antibody) to evaluate its safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and preliminary efficacy in the treatment of solid tumors

    .
    A month ago, the National Medical Products Administration (NMPA) also approved a clinical trial application for the combination of HBM4003 and PD-1 antibody/chemotherapy for the treatment of patients with advanced non-small cell lung cancer and other solid tumors

    .


    Professor Guo Jun, deputy dean of Peking University Cancer Hospital, deputy director of the Beijing Institute of Cancer Prevention and Treatment, and director of the Department of Melanoma, said: “In China, due to the special subtype of melanoma, the current treatments have problems such as poor prognosis and high mortality.
    The effective rate of PD-1 single-agent immunotherapy is only about 16%

    .
    How to improve the effective rate of treatment through innovative solutions and further improve the survival of patients is currently an urgent problem to be solved

    .
    With the development of this research with Platinum Medicine, we It is expected to provide more effective and safer treatment options for Chinese melanoma and other solid tumor patients in the near future

    .
    "


    "HBM4003 is a new generation of anti-CTLA-4 antibody.
    Based on its unique mechanism of action, it has shown good safety and strong anti-tumor activity in preclinical studies

    .
    " Founder, Chairman and CEO of Hebo Medicine Dr.
    Wang Jinsong said, “There are about 4 million new cancer patients in China every year, and there is an urgent need for innovative drugs and new solutions for cancer treatment

    .
    We will actively promote the multi-center clinical research and development process of HBM4003 for multiple cancers, so that the world Cancer patients can extend their lives and improve their quality of life through innovative drugs

    .
    "

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.